Criteria for choosing clinically effective glaucoma treatment: A discussion panel consensus

Current Therapeutic Research - Clinical and Experimental

Volumn 68, Issue 3, 2007, Pages 127-136

  Thygesen, John ^a   Burk, Reinhard ^b   Carassa, Roberto ^c   Crichton, Andrew ^d   Goñi, Francisco Javier ^e   Menage, Mitch ^f   Miglior, Stefano ^g   Montgomery, Donald ^h   Nordmann, John Philippe ⁱ   Roberts, Tim ^j   Singh, Kuldev ^k  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b OWL University   (Germany)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f LEEDS GENERAL INFIRMARY   (United Kingdom)

^g UNIVERSITY OF MILANO BICOCCA   (Italy)

^h GLASGOW ROYAL INFIRMARY   (United Kingdom)

ⁱ CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^j UNIVERSITY OF SYDNEY   (Australia)

^k STANFORD UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

consensus; criteria; glaucoma; intraocular pressure

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; APRACLONIDINE; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; CARBACHOL; CARBONATE DEHYDRATASE INHIBITOR; CLONIDINE; DORZOLAMIDE; LATANOPROST; PILOCARPINE; PROSTAGLANDIN DERIVATIVE; TRAVOPROST;

ARTICLE; CONSENSUS DEVELOPMENT; DRUG EFFICACY; DRUG TOLERABILITY; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; OPEN ANGLE GLAUCOMA; OPTIC NERVE; PATIENT COMPLIANCE; PRIORITY JOURNAL;

EID: 34547927004     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2007.06.002     Document Type: Article

References (18)

1. Sommer A., Katz J., Quigley H., et al. Clinically detectable nerve fiber atrophy precedes the onset of glaucomatous field loss. Arch Ophthalmol 109 (1991) 77-83
2. for the Early Manifest Glaucoma Trial Group. Leske M., Heijl A., Hussein M., et al. Factors for glaucoma progression and the effect of treatment: The early manifest glaucoma trial. Arch Ophthalmol 121 (2003) 48-56
3. for the Barbados Eye Studies Group. Leske M., Connell A., Wu S., et al. Incidence of open-angle glaucoma: The Barbados Eye Studies. Arch Ophthalmol 119 (2001) 89-95
4. Leske M., Connell A., Wu S., et al. Risk factors for open-angle glaucoma. The Barbados Eye Study. Arch Ophthalmol 113 (1995) 918-924
5. discussion 829-830. Kass M., Heuer D., Higginbotham E., et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120 (2002) 701-713
6. for the Early Manifest Glaucoma Trial Group. Heijl A., Leske M., Bengtsson B., et al. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 120 (2002) 1268-1279
7. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130 (2000) 429-440
8. for the GIGTs Study Group. Lichter P., Musch D., Gillespie B., et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 108 (2001) 1943-1953
9. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 126 (1998) 498-505
10. Heithoff K., and Lohr K. Promise and limitations of effectiveness and outcomes research. Summary statement of the IOM Core Committee. Effectiveness and Outcomes in Health Care: Proceedings of an Invitational Conference by the Institute of Medicine Division of Health Care Services (1990), National Academies Press, Washington, DC 8-18
11. Weinreb R., Friedman D., Fechtner R., et al. Risk assessment in the management of patients with ocular hypertension. Am J Ophthalmol 138 (2004) 458-467
12. Weinreb R., and Khaw P. Primary open-angle glaucoma. Lancet 363 (2004) 1711-1720
13. European Glaucoma Society. Terminology and Guidelines for Glaucoma. 2nd ed. (2003), DOGMA Srl, Savona, Italy
14. South East Asia Glaucoma Interest Group. Asia Pacific Glaucoma Guidelines (2004), SEAGIG, Sydney, Australia
15. American Academy of Ophthalmology. Age-Related Macular Degeneration. Preferred Practice Pattern (2003), American Academy of Ophthalmology, San Francisco, Calif
16. Konstas A., Maskaleris G., Gratsonidis S., and Sardelli C. Compliance and viewpoint of glaucoma patients in Greece. Eye 14 (2000) 752-756
17. Taylor S., Galbraith S., and Mills R. Causes of non-compliance with drug regimens in glaucoma patients: A qualitative study. J Ocul Pharmacol Ther 18 (2002) 401-409
18. Nordmann J., Auzanneau N., Richard S., and Berdeaux G. Vision related quality of life and topical glaucoma treatment side effects. Health Qual Life Outcomes 1 (2003) 75